The results of the REDOXS trial have been published in the New England Journal of Medicine. You may view the article here as well as an accompanying NIBBLE (Nutrition Information Byte), a 2-page concise summary of the impact of REDOXS on the future use of glutamine in critically ill patients. Following the publication of the MetaPlus trial, a second NIBBLE was written regarding glutamine supplementation.
A post-hoc analysis by Heyland et al was published in JPEN re-evaluating the effect of glutamine and antioxidant supplementation after controlling for baseline covariates. Results showed that early high doses of glutamine were not beneficial and may have been associated with increased mortality in the critically ill with multi-organ failure. The most harm was seen with both glutamine and antioxidant supplementation in the critically ill with a diagnosis of multi-organ failure including renal failure at time of study enrollment.
On behalf of Dr. Heyland, Rupinder Dhaliwal, Janet Overvelde and the Critical Care Nutrition and Clinical Evaluation Research Unit teams, we would like to thank all our participating sites and collaborators for their support over the years! Here are some important highlights of the research related to the REDOXS Study:
2004-2005 REDOXS Dose Escalating Study
2005-2006 REDOXS Pilot Study
2007-2012 REDOXS Multicentre Definitive Study: 5 countries participated and 45 sites screened 5639 patients to recruit 1223 patients and collect 355,893 pieces of data!